# US 6,913,746 B2 · Complexes of immunoglobulins polysaccharides for oral and transmucosal absorption > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,913,746 B2 - Document ID: US6913746B2 - Status: Granted - Kind: B2 - Application number: 10/081,081 - Filed: 2002-02-20 - Published: 2003-04-10 - Granted: 2005-07-05 - Earliest claimed: 2001-02-21 - Assignees: Grisotech S.A. - Inventors: Rolando Wyss; Bernad Bizzini; Ivo Volpato - Web page: https://patentgrep.com/patent/US6913746B2 ## CPC - A23L 33/19: Dairy proteins - A61K 39/44: Antibodies bound to carriers - A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense} - A61P 19/10: for osteoporosis - A61P 31/04: Antibacterial agents - A61P 31/12: Antivirals - A61P 33/00: Antiparasitic agents - A61P 39/02: Antidotes - A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs - A23V 2250/5434: Immunoglobulines - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention relates to complexes consisting of immunoglobulins and polysaccharides for oral and transmucosal use. The polysaccharides comprised in the complexes according to the invention form an envelope which protects and carries immunoglobulins allowing their systemic absorption through the gastric and mucosal district. Immunoglobulins have a different specificity depending on the required therapeutic effect. They are used in passive immunoprophylaxis for the prevention or therapy of infections caused by pathogenic agents such as virus, bacteria, parasites, or they are used in the modulation of endogenous bio-chemical balances, or in the detoxification from drugs of abuse, medicines, toxins. ## Claims ### Claim 1 An isolated composition consisting of immunoglobulins as the active ingredient, a polysaccharide selected from the group consisting of chitosanes and alginates, wherein the polysaccharidic molecules are neither chemically cross-linked to the immunoglobulins, nor to each other, in combination with suitable excipients and diluents. ### Claim 2 (depends on 1) The composition according to claim 1, wherein the immunoglobulins and the polysaccharides are associated by means of non-covalent links. ### Claim 3 (depends on 1) The composition according to claim 1, wherein the chitosanes are selected from the group consisting of chitosanes with a molecular weight below 150,000 Da, methylglycolchitosane, and salts thereof. ### Claim 4 (depends on 3) The composition according to claim 3, wherein the chitosane is metilglicolchitosane or its salts. ### Claim 5 (depends on 1) The composition according to claim 1, wherein the alginates are selected from the group consisting of polymannuronic acid, alginic acid and its enzymatic fragments, and salts thereof. ### Claim 6 (depends on 1) The composition according to claim 1, wherein said immunoglobulins are selected from the group consisting of IgG, IgA, or their fragments F(ab′)2 or F(ab) or scFv. ### Claim 7 (depends on 6) The composition according to claim 6, wherein said immunoglobulins are IgG or their fragments F(ab′)2 or F(ab) or scFv. ### Claim 8 (depends on 1) The composition according to claim 1, wherein said immunoglobulins are specific for substances selected from the group consisting of toxins, infectious agents, hormones, enzymes, proenzymes, drugs of abuse, medicines, bioactive peptides, metabolites, physiologic precursors and their antigenic components. ### Claim 9 (depends on 8) The composition according to claim 8, wherein said toxins are of mycotic origin. ### Claim 10 (depends on 9) The composition according to claim 9, wherein said toxins are selected from the group consisting of ochratoxin, aflatoxin, zearalonon and fumonisine. ### Claim 11 (depends on 8) The composition according to claim 8, wherein the infectious agents are selected from the group consisting of Herpes simplex virus, cytomegalovirus (CMV), chickenpox virus, rubella virus, syncytial virus, respiratory virus, influenza virus, Epstein-Barr virus, Listeria monocytogenes, Salmonella thipy, Salmonella entheriditis, Salmonella paratiphy, Salmonella thiphymurium, Salmonella choleraensis, Clostridium tetani, Clostridium botulinum or Shigella, Candida albicans, and Toxoplasma gondii. ### Claim 12 (depends on 8) The composition according to claim 8, wherein said drugs of abuse are selected from the group consisting of cocaine, heroin, lysergic acid or their derivatives. ### Claim 13 (depends on 8) The composition according to claim 8, wherein said medicines are selected from the group consisting of monensin, corticosteroids, antibiotics, anticoccidiostatics, antivirus, fungicides, chemiotherapic agents and sympathomimetic agents. ### Claim 14 (depends on 8) The composition according to claim 8, wherein said substances are selected from the following group: a) somatostatin, glucagon cholecystoquinine and growth hormone; b) parathormone and calcitonin; c) pentagastrin; d) thyroid hormone; and e) prothrombin. ### Claim 15 (depends on 11) The composition according to claim 11, for the preparation of food additives. ### Claim 16 (depends on 1) The composition according to claim 1, for oral and transmucosal administration. ### Claim 17 (depends on 16) The composition according to claim 16, wherein said transmucosal administration is perlingual, rectal, vaginal, or buccal.